# Non-ST-Elevation Myocardial Infarction as the Initial Manifestation of Calreticulin-Positive Essential Thrombocythemia: A Case Report

**Authors:** Jared B. Hinton, Jalal S. Jwayyed, Sonum Jagetia, Hunter J. Landwehr, John D. Scrocco

PMC · DOI: 10.3390/jcdd12040157 · 2025-04-16

## TL;DR

A man with no heart disease risk factors had a heart attack caused by a rare blood cancer, highlighting the need to consider blood disorders in unusual heart attack cases.

## Contribution

This case report highlights CALR-mutated essential thrombocythemia as a rare cause of acute coronary syndrome without atherosclerosis.

## Key findings

- A 62-year-old male with no cardiovascular risk factors presented with NSTEMI and was found to have CALR-mutated essential thrombocythemia.
- Treatment with PCI, antiplatelet therapy, and hydroxyurea led to a favorable clinical outcome.
- The case emphasizes the importance of considering hematologic malignancies in atypical myocardial infarction presentations.

## Abstract

Essential thrombocythemia (ET) is a rare myeloproliferative neoplasm characterized by excessive platelet production and a predisposition to thrombotic or hemorrhagic complications. We report a case of a 62-year-old male with no conventional cardiovascular risk factors who presented with a non-ST-segment elevation myocardial infarction (NSTEMI). Initial coronary angiography showed isolated proximal LAD stenosis. Laboratory tests revealed marked thrombocytosis (>1,000,000/μL) and a CALR mutation, confirming a diagnosis of ET. The patient was treated with percutaneous coronary intervention (PCI), dual antiplatelet therapy, and cytoreductive therapy with hydroxyurea, leading to a favorable outcome. This case illustrates how ET, particularly CALR-mutated subtypes, can manifest as acute coronary syndrome in the absence of atherosclerosis and underscores the need to consider hematologic malignancies in atypical presentations of myocardial infarction.

## Linked entities

- **Genes:** CALR (calreticulin) [NCBI Gene 811]
- **Chemicals:** hydroxyurea (PubChem CID 3657)
- **Diseases:** essential thrombocythemia (MONDO:0005029), myeloproliferative neoplasm (MONDO:0020076), acute coronary syndrome (MONDO:0005542)

## Full-text entities

- **Genes:** CALR (calreticulin) [NCBI Gene 811] {aka CALR1, CRT, HEL-S-99n, RO, SSA, cC1qR}
- **Diseases:** hemorrhagic complications (MESH:D006470), thrombocytosis (MESH:D013922), thrombotic or (MESH:D013927), atherosclerosis (MESH:D050197), acute coronary syndrome (MESH:D054058), Myocardial Infarction (MESH:D009203), -Elevation (MESH:D006937), LAD stenosis (MESH:C535887), hematologic malignancies (MESH:D019337), ET (MESH:D013920), myeloproliferative neoplasm (MESH:D009369), NSTEMI (MESH:D000072657)
- **Chemicals:** hydroxyurea (MESH:D006918)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12027719/full.md

---
Source: https://tomesphere.com/paper/PMC12027719